Chronic sickle cell lung disease

New insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension

Roberto Machado, Mark T. Gladwin

Research output: Contribution to journalReview article

89 Citations (Scopus)

Abstract

Pulmonary hypertension is a common complication of sickle cell disease (SCD). In spite of the mild elevations in pulmonary artery pressures in these patients, the associated morbidity and mortality is high. In fact, in adult patients with SCD, pulmonary hypertension is emerging as the major independent risk factor for death. The aetiology of pulmonary hypertension is probably multifactorial, including haemolysis, impaired nitric oxide bioavailability, chronic hypoxaemia, thromboembolism, parenchymal and vascular injury because of sequestration of sickle erythrocytes, chronic liver disease and asplenia. Interestingly, pulmonary hypertension is emerging as a common, and probably, invariant sequella of lifelong haemolytic anaemia in other hereditary and acquired haemolytic diseases, such as thalassaemia, stomatocytosis and spherocytosis. There are currently limited specific data on the effects of any treatment modality for pulmonary hypertension in patients with SCD. It is likely that maximization of SCD therapy, in all patients, and treatment with selective pulmonary vasodilators and antiproliferative agents, in patients with severe disease, would be beneficial. A large trial evaluating the effects of therapy for pulmonary hypertension in the SCD population is clearly indicated.

Original languageEnglish (US)
Pages (from-to)449-464
Number of pages16
JournalBritish Journal of Haematology
Volume129
Issue number4
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Pulmonary Hypertension
Lung Diseases
Therapeutics
Thalassemia
Vascular System Injuries
Hemolytic Anemia
Thromboembolism
Cell- and Tissue-Based Therapy
Hemolysis
Vasodilator Agents
Pulmonary Artery
Biological Availability
Liver Diseases
Nitric Oxide
Chronic Disease
Erythrocytes
Morbidity
Pressure
Lung

Keywords

  • Haemolysis
  • Nitric oxide
  • Pulmonary hypertension
  • Sickle cell disease

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic sickle cell lung disease : New insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. / Machado, Roberto; Gladwin, Mark T.

In: British Journal of Haematology, Vol. 129, No. 4, 01.05.2005, p. 449-464.

Research output: Contribution to journalReview article

@article{4e4cbdd3012b4ef8a7f5343fe99156fd,
title = "Chronic sickle cell lung disease: New insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension",
abstract = "Pulmonary hypertension is a common complication of sickle cell disease (SCD). In spite of the mild elevations in pulmonary artery pressures in these patients, the associated morbidity and mortality is high. In fact, in adult patients with SCD, pulmonary hypertension is emerging as the major independent risk factor for death. The aetiology of pulmonary hypertension is probably multifactorial, including haemolysis, impaired nitric oxide bioavailability, chronic hypoxaemia, thromboembolism, parenchymal and vascular injury because of sequestration of sickle erythrocytes, chronic liver disease and asplenia. Interestingly, pulmonary hypertension is emerging as a common, and probably, invariant sequella of lifelong haemolytic anaemia in other hereditary and acquired haemolytic diseases, such as thalassaemia, stomatocytosis and spherocytosis. There are currently limited specific data on the effects of any treatment modality for pulmonary hypertension in patients with SCD. It is likely that maximization of SCD therapy, in all patients, and treatment with selective pulmonary vasodilators and antiproliferative agents, in patients with severe disease, would be beneficial. A large trial evaluating the effects of therapy for pulmonary hypertension in the SCD population is clearly indicated.",
keywords = "Haemolysis, Nitric oxide, Pulmonary hypertension, Sickle cell disease",
author = "Roberto Machado and Gladwin, {Mark T.}",
year = "2005",
month = "5",
day = "1",
doi = "10.1111/j.1365-2141.2005.05432.x",
language = "English (US)",
volume = "129",
pages = "449--464",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Chronic sickle cell lung disease

T2 - New insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension

AU - Machado, Roberto

AU - Gladwin, Mark T.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Pulmonary hypertension is a common complication of sickle cell disease (SCD). In spite of the mild elevations in pulmonary artery pressures in these patients, the associated morbidity and mortality is high. In fact, in adult patients with SCD, pulmonary hypertension is emerging as the major independent risk factor for death. The aetiology of pulmonary hypertension is probably multifactorial, including haemolysis, impaired nitric oxide bioavailability, chronic hypoxaemia, thromboembolism, parenchymal and vascular injury because of sequestration of sickle erythrocytes, chronic liver disease and asplenia. Interestingly, pulmonary hypertension is emerging as a common, and probably, invariant sequella of lifelong haemolytic anaemia in other hereditary and acquired haemolytic diseases, such as thalassaemia, stomatocytosis and spherocytosis. There are currently limited specific data on the effects of any treatment modality for pulmonary hypertension in patients with SCD. It is likely that maximization of SCD therapy, in all patients, and treatment with selective pulmonary vasodilators and antiproliferative agents, in patients with severe disease, would be beneficial. A large trial evaluating the effects of therapy for pulmonary hypertension in the SCD population is clearly indicated.

AB - Pulmonary hypertension is a common complication of sickle cell disease (SCD). In spite of the mild elevations in pulmonary artery pressures in these patients, the associated morbidity and mortality is high. In fact, in adult patients with SCD, pulmonary hypertension is emerging as the major independent risk factor for death. The aetiology of pulmonary hypertension is probably multifactorial, including haemolysis, impaired nitric oxide bioavailability, chronic hypoxaemia, thromboembolism, parenchymal and vascular injury because of sequestration of sickle erythrocytes, chronic liver disease and asplenia. Interestingly, pulmonary hypertension is emerging as a common, and probably, invariant sequella of lifelong haemolytic anaemia in other hereditary and acquired haemolytic diseases, such as thalassaemia, stomatocytosis and spherocytosis. There are currently limited specific data on the effects of any treatment modality for pulmonary hypertension in patients with SCD. It is likely that maximization of SCD therapy, in all patients, and treatment with selective pulmonary vasodilators and antiproliferative agents, in patients with severe disease, would be beneficial. A large trial evaluating the effects of therapy for pulmonary hypertension in the SCD population is clearly indicated.

KW - Haemolysis

KW - Nitric oxide

KW - Pulmonary hypertension

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=20044386727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044386727&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05432.x

DO - 10.1111/j.1365-2141.2005.05432.x

M3 - Review article

VL - 129

SP - 449

EP - 464

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -